尊龙凯时·(中国)人生就是搏!

On February 22, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") signed a strategic cooperation agreement and the first cooperative technology development agreement with the Second Xiangya Hospital of Central South University. The signing ceremony is also the unveiling ceremony for the strategic cooperation base of the two parties.

This strategic partnership aims to establish an innovation mechanism that connects the industry, academia, research institutes and hospitals. The two parties will leverage the resources of each other in terms of talent cultivation, drug R&D, clinical trial application, and product commercialization to promote the application and monetization of scientific achievements. This move will further drive the Company's innovation, transformation and development, help it build up a high-caliber R&D team, and facilitate faster, broader, and deeper innovation in the field of endocrine treatment. In this way, the Company will be able to pursue innovation-driven development and create quality outcomes in the long term.

Attending the signing ceremony were Li Zhihong, Vice President of Central South University and President of the Second Xiangya Hospital, Huang Jiangsheng, Vice President of the Second Xiangya Hospital, Fei Yun, Chief Accountant of the Second Xiangya Hospital, Zhou Zhiguang, Director of the National Clinical Research Center for Metabolic Diseases, as well as leaders of relevant functional departments from the Second Xiangya Hospital. Other attendees from Tonghua Dongbao included Du Zhiqiang, R&D Deputy General Manager, Zhang Wenhai, Sales Deputy General Manager, Zhang Guodong, Sales Deputy General Manager, and other company leaders. The signing ceremony was presided over by Mr. Huang Jiangsheng.

At the meeting, Mr. Li Zhihong delivered a warm welcome speech. He mentioned that the hospital placed much emphasis on enterprise-academy cooperation in the current development stage. As the National Clinical Research Center for Metabolic Diseases grows rapidly, the four-in-one cooperation mode will further contribute to a win-win situation for both parties. Professor Zhou Zhiguang introduced the basic information of the Second Xiangya Hospital and the National Clinical Research Center for Metabolic Diseases. Dr. Du Zhiqiang introduced Tonghua Dongbao's basic situation and development history. He extended the expectation to cooperate with the Second Xiangya Hospital and the National Clinical Research Center for Metabolic Diseases in basic research, clinical R&D, and talent cultivation, in line with the Company's innovative development concept. Through the cooperation, the Company will boost its innovative R&D capabilities, promote the commercialization of scientific achievements, and develop high-quality, novel drugs catering to the needs of patients.